​

Spyre Therapeutics (SYRE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SYRE Stock Forecast

Spyre Therapeutics (SYRE) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $43.00, with a high of $43.00 and a low of $43.00. This represents a 75.01% increase from the last price of $24.57.

$20 $25 $30 $35 $40 $45 High: $43 Avg: $43 Low: $43 Last Closed Price: $24.57

SYRE Stock Rating

Spyre Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

SYRE Price Target Upside V Benchmarks

TypeNameUpside
StockSpyre Therapeutics75.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$43.00$57.00
Last Closing Price$24.57$24.57$24.57
Upside/Downside-75.01%131.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-131--14
Sep, 25-121--13
Aug, 25-121--13
Jul, 25-121--13
Jun, 25-111--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 26, 2025Deutsche Bank$43.00$16.24164.78%75.01%
Nov 12, 2024Alex ThompsonStifel Nicolaus$71.00$35.5299.89%188.97%
Oct 17, 2024Colleen KusyRobert W. Baird$50.00$32.3754.46%103.50%
Oct 15, 2024Yanan ZhuWells Fargo$40.00$30.6630.46%62.80%
May 10, 2024Julian HarrisonBTIG$40.00$35.1913.67%62.80%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 26, 2025Deutsche BankBuyinitialise
Oct 15, 2024Wells FargoOverweightOverweighthold
Oct 14, 2024Cowen & Co.BuyBuyhold
Sep 25, 2024BTIGBuyBuyhold
Sep 03, 2024WedbushOutperforminitialise
Jul 16, 2024Evercore ISIOutperforminitialise
May 10, 2024BTIGBuyBuyhold
Mar 01, 2024Wells FargoOverweightupgrade

Financial Forecast

EPS Forecast

$-50 $-40 $-30 $-20 $-10 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-25.02$-24.86$-46.15$-0.56----
Avg Forecast$-24.97$-26.92$-7.51$-4.27$-3.86$-4.15$-4.74$-4.32
High Forecast$-24.97$-26.92$-7.51$-3.98$-3.05$-2.62$-2.58$-4.32
Low Forecast$-24.97$-26.92$-7.51$-4.52$-4.49$-5.66$-6.61$-4.32
Surprise %0.20%-7.65%514.51%-86.89%----

Revenue Forecast

$0 $4M $8M $12M $16M $20M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.74M$2.33M$886.00K-----
Avg Forecast$18.36M$2.23M$1.12M$2.99M$4.70M$166.67K$136.21K$85.29K
High Forecast$18.36M$2.23M$1.18M$2.99M$4.70M$166.67K$136.21K$85.29K
Low Forecast$18.36M$2.23M$1.06M$2.99M$4.70M$166.67K$136.21K$85.29K
Surprise %2.05%4.42%-20.69%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.80M$-83.81M$-338.79M$-208.02M----
Avg Forecast$-172.21M$-185.65M$-55.11M$-31.21M$-27.67M$-30.37M$-33.75M$-31.73M
High Forecast$-172.21M$-185.65M$-55.11M$-29.21M$-22.38M$-19.21M$-18.96M$-31.73M
Low Forecast$-172.21M$-185.65M$-55.11M$-33.21M$-32.97M$-41.53M$-48.54M$-31.73M
Surprise %-61.79%-54.85%514.76%566.46%----

SYRE Forecast FAQ

Is Spyre Therapeutics stock a buy?

Spyre Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spyre Therapeutics is a favorable investment for most analysts.

What is Spyre Therapeutics's price target?

Spyre Therapeutics's price target, set by 5 Wall Street analysts, averages $43 over the next 12 months. The price target range spans from $43 at the low end to $43 at the high end, suggesting a potential 75.01% change from the previous closing price of $24.57.

How does Spyre Therapeutics stock forecast compare to its benchmarks?

Spyre Therapeutics's stock forecast shows a 75.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Spyre Therapeutics over the past three months?

  • October 2025: 0% Strong Buy, 92.86% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 92.31% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 92.31% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Spyre Therapeutics’s EPS forecast?

Spyre Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.86, marking a 589.29% increase from the reported $-0.56 in 2024. Estimates for the following years are $-4.15 in 2026, $-4.74 in 2027, and $-4.32 in 2028.

What is Spyre Therapeutics’s revenue forecast?

Spyre Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.7M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $166.67K, followed by $136.21K for 2027, and $85.29K for 2028.

What is Spyre Therapeutics’s net income forecast?

Spyre Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-27.674M, representing a -86.70% decrease from the reported $-208M in 2024. Projections indicate $-30.37M in 2026, $-33.75M in 2027, and $-31.728M in 2028.